Lynne Jesaitis

BioMarin (United States) — United States

Medicine · Health Sciences

11h-index2.2kcitations16works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lysosomal Storage Disorders Research(7), Trypanosoma species research and implications(5), Monoclonal and Polyclonal Antibodies Research(3), Cancer-related molecular mechanisms research(2), Multiple Myeloma Research and Treatments(2)

Publications16 total

2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( <u>Part 3</u> –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene &amp; Cell Therapy and Vaccine Assays)
Bioanalysis·2021· 60 cited
Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Journal of Visualized Experiments·2018· 1 citedOpen Access
Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Journal of Visualized Experiments·2018· 4 citedOpen Access
Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment
Molecular Genetics and Metabolism·2018· 25 citedOpen Access
Safety, efficacy, and immunogenicity of elosulfase alfa in patients with Morquio syndrome type A participating in 2 sequential open-label studies (MOR-002/MOR-100), representing 5 years of treatment
Molecular Genetics and Metabolism·2018
Development of an electrochemiluminescent assay to measure LAMP2 in canine cerebrospinal fluid samples
Molecular Genetics and Metabolism·2017
Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study
Clinical Therapeutics·2016· 34 citedOpen Access
Antibodies that neutralize cellular uptake of elosulfase alfa are not associated with reduced efficacy or pharmacodynamic effect in individuals with Morquio A syndrome
Journal of Immunological Methods·2016· 17 citedOpen Access
Table of Contents
Clinical Therapeutics·2015Open Access
Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial
Clinical Therapeutics·2014· 55 cited
Pharmacokinetic and Pharmacodynamic Evaluation of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients with Morquio A Syndrome
Clinical Pharmacokinetics·2014· 40 citedOpen Access
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu
Blood·2007· 468 citedOpen Access
Eradication of Tumors in Pre-Clinical Models of Multiple Myeloma by Anti-CS1 Monoclonal Antibody HuLuc63: Mechanism of Action Studies.
Blood·2006· 11 cited
The <i>extended auricle1</i> (<i>eta1</i>) Gene Is Essential for the Genetic Network Controlling Postinitiation Maize Leaf Development
Genetics·2003· 14 cited
The Tight Junction Protein ZO-1 Establishes a Link between the Transmembrane Protein Occludin and the Actin Cytoskeleton
Journal of Biological Chemistry·1998· 1.4k citedOpen Access
The Tight Junction Protein ZO-2 Contains Three PDZ (PSD-95Discs-LargeZO-1) Domains and an Alternatively Spliced Region
Journal of Biological Chemistry·1996· 101 citedOpen Access

Frequent Co-authors

Becky Schweighardt(6), Troy Tompkins(5), Yulan Qi(5), Charles O’Neill(4), Brian Long(4), Celeste Decker(4), Andrew C. Melton(4), Stephen J. Zoog(4), Donald G. Musson(3), Adam J. Shaywitz(3), Myles Dillon(2), Audie Rice(2), Anne van Abbema(2), Ingrid W. Caras(2), Debbie A. Law(2), Daniel Afar(2), Kelly Lau(2), Pamela J. Farmer(2), Christine Haller(2), Kehu Yang(2)